{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T04:44:34Z","timestamp":1762836274064,"version":"build-2065373602"},"reference-count":89,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","award":["R33 MH123603"],"award-info":[{"award-number":["R33 MH123603"]}],"id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Computerized auditory training (AT) modestly improves symptoms, cognition, and functioning in schizophrenia. We assessed whether d-amphetamine (AMPH) or memantine (MEM) can enhance gains from 30-h of AT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Antipsychotic-medicated individuals with chronic psychosis (n\u2005=\u200568; mean age 47.03y; M:F\u2005=\u200539:29) completed up to 30 AT sessions (2-3\/week; n\u2005=\u200550 completed 30 sessions) in 3 groups: \u201cAMPH group\u201d (AMPH (5\u00a0mg po) 1-h before each AT session); \u201cMEM group\u201d (titrated to 10\u00a0mg MEM bid and maintained that dose throughout training); \u201cPBO group\u201d (PBO dosed identically to either AMPH or MEM). Primary (PANSS total, MCCB Composite, WHODAS) and secondary (PANSS positive, PANSS negative, YMRS, PHQ-9, PSYRATS) outcome measures were acquired at baseline, after 10, 20, and 30 AT sessions, and 12 weeks post-training. Pill identity (active\/PBO) was blind to subjects and staff.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Marginally significant between-group gains for AMPH vs PBO were detected for one of three primary outcomes (WHODAS, P =.050; but not PANSS total or MCCB Composite), and for 3 of 5 secondary clinical outcomes (PANSS positive, YMRS, PSYRATS, P\u2019s\u2264.027\u2013.049). Within-subject gains over time were detected for primary and secondary clinical measures for AMPH (P\u2019s\u2264.014\u2013.004) and MEM (P\u2019s\u2264.02\u2013.001) groups; some of these would not survive conservative correction for multiple comparisons. No measures detected symptom worsening; treatment satisfaction exceeded subjects\u2019 expectations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Results are mixed; drug-associated gains in several measures vs PBO suggest that these regimens may augment AT-induced functional and clinical improvement in psychosis patients, independent of changes in neurocognition. Assessment in larger samples seems warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/schbul\/sbaf015","type":"journal-article","created":{"date-parts":[[2025,2,9]],"date-time":"2025-02-09T23:15:52Z","timestamp":1739142952000},"page":"1529-1544","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacologic Augmentation of Computerized Auditory Training in Chronic Psychosis: Preliminary Findings From a Single-Site, Double-Blind Study"],"prefix":"10.1093","volume":"51","author":[{"given":"Neal R","family":"Swerdlow","sequence":"first","affiliation":[{"name":"Department of Psychiatry, UCSD School of Medicine, La Jolla, CA \u00a092093,\u00a0","place":["United States"]},{"name":"VISN-22 Mental Illness Research Education and Clinical Center, VA San Diego Healthcare System, La Jolla, CA \u00a092037,\u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0225-9422","authenticated-orcid":false,"given":"Joyce","family":"Sprock","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, UCSD School of Medicine, La Jolla, CA \u00a092093,\u00a0","place":["United States"]},{"name":"VISN-22 Mental Illness Research Education and Clinical Center, VA San Diego Healthcare System, La Jolla, CA \u00a092037,\u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, UCSD School of Medicine, La Jolla, CA \u00a092093,\u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jenny Min","family":"Din","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, UCSD School of Medicine, La Jolla, CA \u00a092093,\u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica","family":"Minhas","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, UCSD School of Medicine, La Jolla, CA \u00a092093,\u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo","family":"Talledo","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, UCSD School of Medicine, La Jolla, CA \u00a092093,\u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yash B","family":"Joshi","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, UCSD School of Medicine, La Jolla, CA \u00a092093,\u00a0","place":["United States"]},{"name":"VISN-22 Mental Illness Research Education and Clinical Center, VA San Diego Healthcare System, La Jolla, CA \u00a092037,\u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan L","family":"Molina","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, UCSD School of Medicine, La Jolla, CA \u00a092093,\u00a0","place":["United States"]},{"name":"VISN-22 Mental Illness Research Education and Clinical Center, VA San Diego Healthcare System, La Jolla, CA \u00a092037,\u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bethany","family":"Nordberg","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, UCSD School of Medicine, La Jolla, CA \u00a092093,\u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Ing","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, UCSD School of Medicine, La Jolla, CA \u00a092093,\u00a0","place":["United States"]},{"name":"VISN-22 Mental Illness Research Education and Clinical Center, VA San Diego Healthcare System, La Jolla, CA \u00a092037,\u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3026-7609","authenticated-orcid":false,"given":"Michael L","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Psychology, Colorado State University, Fort Collins, CO 80523,\u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory A","family":"Light","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, UCSD School of Medicine, La Jolla, CA \u00a092093,\u00a0","place":["United States"]},{"name":"VISN-22 Mental Illness Research Education and Clinical Center, VA San Diego Healthcare System, La Jolla, CA \u00a092037,\u00a0","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"2025111023421339600_CIT0001","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.biopsych.2007.05.022","article-title":"Predicting schizophrenia patients\u2019 real-world behavior with specific neuropsychological and functional capacity measures","volume":"63","author":"Bowie","year":"2008","journal-title":"Biol Psychiatry."},{"key":"2025111023421339600_CIT0002","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1176\/ajp.153.3.321","article-title":"What are the functional consequences of neurocognitive deficits in schizophrenia","volume":"153","author":"Green","year":"1996","journal-title":"Am J Psychiatry."},{"key":"2025111023421339600_CIT0003","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1192\/bjp.165.4.486","article-title":"Predicting symptomatic and behavioural outcomes of community care","volume":"165","author":"Wykes","year":"1994","journal-title":"Br J Psychiatry."},{"key":"2025111023421339600_CIT0004","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1001\/archpsyc.64.6.633","article-title":"Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial","volume":"64","author":"Keefe","year":"2007","journal-title":"Arch Gen Psychiatry."},{"key":"2025111023421339600_CIT0005","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/NMD.0b013e3181be7422","article-title":"A preliminary controlled trial of cognitive behavioral therapy in clozapine resistant schizophrenia","volume":"197","author":"Barretto","year":"2009","journal-title":"J Nerv Ment Dis."},{"key":"2025111023421339600_CIT0006","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/archgenpsychiatry.2010.63","article-title":"Neuroprotective effects of cognitive enhancement therapy against gray matter loss in early schizophrenia: results from a 2-year randomized controlled trial","volume":"67","author":"Eack","year":"2010","journal-title":"Arch Gen Psychiatry."},{"key":"2025111023421339600_CIT0007","doi-asserted-by":"crossref","first-page":"730","DOI":"10.4088\/JCP.v68n0510","article-title":"Randomized controlled trial of cognitive behavioral social skills training for older people with schizophrenia: 12-month follow-up","volume":"68","author":"Granholm","year":"2007","journal-title":"J Clin Psychiatry."},{"key":"2025111023421339600_CIT0008","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1080\/15487760701853326","article-title":"Supported employment for middle-aged and older people with schizophrenia","volume":"11","author":"Twamley","year":"2008","journal-title":"Am J Psychiatr Rehabil"},{"key":"2025111023421339600_CIT0009","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1080\/15487760801963678","article-title":"Development and pilot testing of a novel compensatory cognitive training intervention for people with psychosis","volume":"11","author":"Twamley","year":"2008","journal-title":"Am J Psychiatr Rehabil."},{"key":"2025111023421339600_CIT0010","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/schbul\/sbn182","article-title":"Work, recovery, and comorbidity in schizophrenia: a randomized controlled trial of cognitive remediation","volume":"35","author":"McGurk","year":"2009","journal-title":"Schizophr Bull."},{"key":"2025111023421339600_CIT0011","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1176\/appi.ajp.20230396","article-title":"Durability of effects of cognitive remediation on cognition and psychosocial functioning in schizophrenia: A systematic review and meta-analysis of randomized clinical trials","volume":"181","author":"Vita","year":"2024","journal-title":"Am J Psychiatry."},{"key":"2025111023421339600_CIT0012","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1176\/appi.ajp.20240281","article-title":"Cognitive remediation in schizophrenia spectrum illness: Evidence for treatment persistence","volume":"181","author":"Kurtz","year":"2024","journal-title":"Am J Psychiatry."},{"key":"2025111023421339600_CIT0013","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1176\/appi.ajp.2007.07060906","article-title":"A meta-analysis of cognitive remediation in schizophrenia","volume":"164","author":"McGurk","year":"2007","journal-title":"Am J Psychiatry."},{"key":"2025111023421339600_CIT0014","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1176\/appi.ajp.2009.08050757","article-title":"Using neuroplasticity-based auditory training to improve verbal memory in schizophrenia","volume":"166","author":"Fisher","year":"2009","journal-title":"Am J Psychiatry."},{"key":"2025111023421339600_CIT0015","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/schbul\/sbn170","article-title":"Neuroplasticity-based cognitive training in schizophrenia: an interim report on the effects 6 months later","volume":"36","author":"Fisher","year":"2010","journal-title":"Schizophr Bull."},{"key":"2025111023421339600_CIT0016","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/npp.2011.251","article-title":"Cognitive training for impaired neural systems in neuropsychiatric illness","volume":"37","author":"Vinogradov","year":"2012","journal-title":"Neuropsychopharmacology."},{"key":"2025111023421339600_CIT0017","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.schres.2018.07.025","article-title":"Targeted cognitive training improves auditory and verbal outcomes among treatment refractory schizophrenia patients mandated to residential care","volume":"202","author":"Thomas","year":"2018","journal-title":"Schizophr Res."},{"key":"2025111023421339600_CIT0018","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.schres.2018.06.024","article-title":"Computerized cognitive training is associated with improved psychosocial treatment engagement in schizophrenia","volume":"202","author":"Thomas","year":"2018","journal-title":"Schizophr Res."},{"key":"2025111023421339600_CIT0019","doi-asserted-by":"crossref","first-page":"100171","DOI":"10.1016\/j.scog.2019.100171","article-title":"Six month durability of targeted cognitive training supplemented with social cognition exercises in schizophrenia","volume":"20","author":"Miley","year":"2019","journal-title":"Schizophr Res Cogn"},{"key":"2025111023421339600_CIT0020","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/schbul\/sbab102","article-title":"Durable cognitive gains and symptom improvement are observed in individuals with recent-onset schizophrenia 6 months after a randomized trial of auditory training completed remotely","volume":"48","author":"Loewy","year":"2022","journal-title":"Schizophr Bull."},{"key":"2025111023421339600_CIT0021","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.4088\/JCP.11m07100","article-title":"Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial","volume":"73","author":"Keefe","year":"2012","journal-title":"J Clin Psychiatry."},{"key":"2025111023421339600_CIT0022","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.schres.2012.01.042","article-title":"Computerized cognitive remediation training for schizophrenia: an open label, multi-site, multinational methodology study","volume":"139","author":"Murthy","year":"2012","journal-title":"Schizophr Res."},{"key":"2025111023421339600_CIT0023","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1093\/schbul\/sbt232","article-title":"Neuroplasticity-based auditory training via laptop computer improves cognition in young individuals with recent onset schizophrenia","volume":"41","author":"Fisher","year":"2015","journal-title":"Schizophr Bull."},{"key":"2025111023421339600_CIT0024","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.schres.2020.05.017","article-title":"Auditory versus visual neuroscience-informed cognitive training in schizophrenia: Effects on cognition, symptoms and quality of life","volume":"222","author":"Scoriels","year":"2020","journal-title":"Schizophr Res."},{"key":"2025111023421339600_CIT0025","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.1093\/schbul\/sbw009","article-title":"Intensive auditory cognitive training improves verbal memory in adolescents and young adults at clinical high risk for psychosis","volume":"42","author":"Loewy","year":"2016","journal-title":"Schizophr Bull."},{"key":"2025111023421339600_CIT0026","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.neuroimage.2014.05.057","article-title":"Intensive cognitive training in schizophrenia enhances working memory and associated prefrontal cortical efficiency in a manner that drives long-term functional gains","volume":"99","author":"Subramaniam","year":"2014","journal-title":"Neuroimage."},{"key":"2025111023421339600_CIT0027","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.schres.2018.07.034","article-title":"The efficacy of computerized cognitive drill and practice training for patients with a schizophrenia-spectrum disorder: A meta-analysis","volume":"204","author":"Prikken","year":"2019","journal-title":"Schizophr Res."},{"key":"2025111023421339600_CIT0028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2011.05.004","article-title":"Are we studying and treating schizophrenia correctly","volume":"130","author":"Swerdlow","year":"2011","journal-title":"Schizophr Res."},{"key":"2025111023421339600_CIT0029","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/npp.2011.195","article-title":"Beyond antipsychotics: Pharmacologically-augmented cognitive therapies (PACTs) for schizophrenia","volume":"37","author":"Swerdlow","year":"2011","journal-title":"Neuropsychopharmacology."},{"key":"2025111023421339600_CIT0030","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/7854_2010_39","article-title":"Pharmacological strategies for enhancing cognition in schizophrenia","volume":"4","author":"Barch","year":"2010","journal-title":"Curr Top Behav Neurosci"},{"key":"2025111023421339600_CIT0031","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1176\/appi.ajp.2007.06081358","article-title":"The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments","volume":"164","author":"Buchanan","year":"2007","journal-title":"Am J Psychiatry."},{"key":"2025111023421339600_CIT0032","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/jcp.0b013e31815abf34","article-title":"Lamotrigine as add-on therapy in schizophrenia: results of 2 placebo-controlled trials","volume":"27","author":"Goff","year":"2007","journal-title":"J Clin Psychopharmacol."},{"key":"2025111023421339600_CIT0033","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archpsyc.56.1.21","article-title":"A placebo-controlled trial of D-cycloserine added to conventional neuroleptics in patients with schizophrenia","volume":"56","author":"Goff","year":"1999","journal-title":"Arch Gen Psychiatry."},{"key":"2025111023421339600_CIT0034","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1176\/ajp.153.12.1628","article-title":"D-cycloserine added to clozapine for patients with schizophrenia","volume":"153","author":"Goff","year":"1996","journal-title":"Am J Psychiatry."},{"key":"2025111023421339600_CIT0035","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1176\/ajp.2007.164.7.992","article-title":"Cognition, drug treatment, and functional outcome in schizophrenia: A tale of two transitions","volume":"164","author":"Green","year":"2007","journal-title":"Am J Psychiatry."},{"key":"2025111023421339600_CIT0036","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/7854_2009_10","article-title":"Pharmacological enhancement of behavioral therapy: focus on posttraumatic stress disorder","volume":"2","author":"Choi","year":"2010","journal-title":"Curr Top Behav Neurosci"},{"key":"2025111023421339600_CIT0037","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1001\/archpsyc.61.11.1136","article-title":"Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear","volume":"61","author":"Ressler","year":"2004","journal-title":"Arch Gen Psychiatry."},{"key":"2025111023421339600_CIT0038","first-page":"872","article-title":"Amphetamine enhances gains in auditory discrimination training in adult schizophrenia patients","volume":"43","author":"Swerdlow","year":"2017","journal-title":"Schizophr Bull."},{"key":"2025111023421339600_CIT0039","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1017\/S0033291721001239","article-title":"Auditory discrimination and frequency modulation learning in schizophrenia patients: amphetamine within-subject dose response and time course","volume":"53","author":"Swerdlow","year":"2023","journal-title":"Psychol Med."},{"key":"2025111023421339600_CIT0040","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1038\/s41386-020-00865-8","article-title":"Memantine effects on auditory discrimination and training in schizophrenia patients","volume":"45","author":"Swerdlow","year":"2020","journal-title":"Neuropsychopharmacology."},{"key":"2025111023421339600_CIT0041","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J Clin Psychiatry."},{"key":"2025111023421339600_CIT0042","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/schbul\/sbp068","article-title":"When top-down meets bottom-up: auditory training enhances verbal memory in schizophrenia","volume":"35","author":"Adcock","year":"2009","journal-title":"Schizophr Bull."},{"key":"2025111023421339600_CIT0043","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1037\/neu0000311","article-title":"Engagement with the auditory processing system during targeted auditory cognitive training mediates changes in cognitive outcomes in individuals with schizophrenia","volume":"30","author":"Biagianti","year":"2016","journal-title":"Neuropsychology."},{"key":"2025111023421339600_CIT0044","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.schres.2021.07.033","article-title":"Central auditory processing deficits in schizophrenia: Effects of auditory-based cognitive training","volume":"236","author":"Molina","year":"2021","journal-title":"Schizophr Res."},{"key":"2025111023421339600_CIT0045","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/s41398-020-01089-6","article-title":"Gamma oscillations predict pro-cognitive and clinical response to auditory-based cognitive training in schizophrenia","volume":"10","author":"Molina","year":"2020","journal-title":"Transl Psychiatry."},{"key":"2025111023421339600_CIT0046","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/s41386-018-0256-9","article-title":"Neurophysiologic measures of target engagement predict response to auditory-based cognitive training in treatment refractory schizophrenia","volume":"44","author":"Hochberger","year":"2019","journal-title":"Neuropsychopharmacology."},{"key":"2025111023421339600_CIT0047","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.schres.2019.11.015","article-title":"Oscillatory biomarkers of early auditory information processing predict cognitive gains following targeted cognitive training in schizophrenia patients","volume":"215","author":"Hochberger","year":"2019","journal-title":"Schizophr Res."},{"key":"2025111023421339600_CIT0048","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.schres.2019.01.016","article-title":"Verbal learning deficits associated with increased anticholinergic burden are attenuated with targeted cognitive training in treatment refractory schizophrenia patients","volume":"208","author":"Joshi","year":"2019","journal-title":"Schizophr Res."},{"key":"2025111023421339600_CIT0049","doi-asserted-by":"crossref","DOI":"10.1017\/S0033291724000783","article-title":"Early auditory processing abnormalities alter individual learning trajectories and sensitivity to computerized cognitive training in schizophrenia","author":"Molina","year":"2024","journal-title":"Psychol Med."},{"key":"2025111023421339600_CIT0050","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.schres.2016.01.019","article-title":"Measuring the capacity for auditory system plasticity: An examination of performance gains during initial exposure to auditory-targeted cognitive training in schizophrenia","volume":"172","author":"Tarasenko","year":"2016","journal-title":"Schizophr Res."},{"key":"2025111023421339600_CIT0051","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1176\/appi.ajp.2011.10111704","article-title":"The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults","volume":"168","author":"Posner","year":"2011","journal-title":"Am J Psychiatry."},{"key":"2025111023421339600_CIT0052","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/npp.2015.162","article-title":"Memantine effects on sensorimotor gating and mismatch negativity in patients with chronic psychosis","volume":"41","author":"Swerdlow","year":"2016","journal-title":"Neuropsychopharm"},{"key":"2025111023421339600_CIT0053","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1038\/npp.2017.81","article-title":"Single-dose memantine improves cortical oscillatory response dynamics in patients with schizophrenia","volume":"42","author":"Light","year":"2017","journal-title":"Neuropsychopharmacology."},{"key":"2025111023421339600_CIT0054","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull."},{"key":"2025111023421339600_CIT0055","doi-asserted-by":"crossref","first-page":"815","DOI":"10.2471\/BLT.09.067231","article-title":"Developing the World Health Organization Disability Assessment Schedule 2.0","volume":"88","author":"Ustun","year":"2010","journal-title":"Bull World Health Organ."},{"key":"2025111023421339600_CIT0056","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/jama.282.18.1737","article-title":"Patient Health Questionnaire Study Group. Validity and utility of a self-report version of PRIME-MD: the PHQ Primary Care Study","volume":"282","author":"Spitzer","year":"1999","journal-title":"JAMA."},{"key":"2025111023421339600_CIT0057","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br J Psychiatry."},{"key":"2025111023421339600_CIT0058","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1017\/S0033291799008661","article-title":"Scales to measure dimensions of hallucinations and delusions: the psychotic symptom rating scales (PSYRATS)","volume":"29","author":"Haddock","year":"1999","journal-title":"Psychol Med."},{"key":"2025111023421339600_CIT0059","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-4419-0318-1_1","article-title":"Linear mixed-effects models: Basic concepts and examples","volume-title":"Mixed-Effects Models in S and S-PLUS","author":"Pinheiro","year":"2000"},{"key":"2025111023421339600_CIT0060","volume-title":"Statistical Power Analysis for the Behavioral Sciences","author":"Cohen","year":"1988","edition":"2nd ed"},{"volume-title":"Understanding the New Statistics: Effect Sizes, Confidence Intervals, and Meta-Analysis","year":"2012","author":"Cumming","key":"2025111023421339600_CIT0061"},{"key":"2025111023421339600_CIT0062","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1037\/0003-066X.45.12.1304","volume":"45","author":"Cohen","year":"1990","journal-title":". Am Psychol"},{"key":"2025111023421339600_CIT0063","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0306-4530(92)90013-W","article-title":"Reporting the size of effects in research studies to facilitate assessment of practical or clinical significance","volume":"17","author":"Kraemer","year":"1992","journal-title":"Psychoneuroendocrinology."},{"key":"2025111023421339600_CIT0064","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/eat.23216","article-title":"Wrangling with p-values versus effect sizes to improve medical decision-making: A tutorial","volume":"53","author":"Kraemer","year":"2020","journal-title":"Int J Eat Disord."},{"key":"2025111023421339600_CIT0065","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1001\/jamapsychiatry.2017.1574","article-title":"Placebo response and practice effects in schizophrenia cognition trials","volume":"74","author":"Keefe","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"2025111023421339600_CIT0066","first-page":"534","article-title":"ECDEU Assessment manual for psychopharmacology","volume-title":"Abnormal Involuntary Movement Scale (117-AIMS)","author":"Guy","year":"1996"},{"key":"2025111023421339600_CIT0067","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.jsat.2007.05.007","article-title":"Psychometric evaluation of the amphetamine cessation symptom assessment","volume":"34","author":"McGregor","year":"2008","journal-title":"J Subst Abuse Treat."},{"key":"2025111023421339600_CIT0068","article-title":"Dextroamphetamine-Amphetamine","volume-title":"StatPearls","author":"Shoar","year":"2024"},{"key":"2025111023421339600_CIT0069","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1038\/npp.2013.111","article-title":"Adjunctive lisdexamfetamine dimesylate therapy in adult outpatients with predominant negative symptoms of schizophrenia: open-label and randomized-withdrawal phases","volume":"38","author":"Lasser","year":"2013","journal-title":"Neuropsychopharmacology."},{"key":"2025111023421339600_CIT0070","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1007\/s00213-017-4616-7","article-title":"Memantine add-on to antipsychotic treatment for residual negative and cognitive symptoms of schizophrenia: a meta-analysis","volume":"234","author":"Kishi","year":"2017","journal-title":"Psychopharmacology (Berl)."},{"key":"2025111023421339600_CIT0071","doi-asserted-by":"crossref","first-page":"102473","DOI":"10.1016\/j.eclinm.2024.102473","article-title":"Comprehensive evaluation of 45 augmentation drugs for schizophrenia: a network meta-analysis","volume":"69","author":"Etchecopar-Etchart","year":"2024","journal-title":"EClinicalMedicine"},{"key":"2025111023421339600_CIT0072","first-page":"253","article-title":"Augmentation of Antipsychotic Treatment with Memantine in Patients with Schizophrenia: A Systematic Review and Meta-Analysis","volume":"30","author":"Vay\u0131so\u011flu","year":"2019","journal-title":"Turk Psikiyatri Derg."},{"key":"2025111023421339600_CIT0073","doi-asserted-by":"crossref","first-page":"103375","DOI":"10.1016\/j.ajp.2022.103375","article-title":"Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment","volume":"79","author":"Yeh","year":"2023","journal-title":"Asian J Psychiatr"},{"key":"2025111023421339600_CIT0074","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.schres.2019.05.019","article-title":"Adjunctive memantine for major mental disorders: A systematic review and meta-analysis of randomized double-blind controlled trials","volume":"209","author":"Zheng","year":"2019","journal-title":"Schizophr Res."},{"key":"2025111023421339600_CIT0075","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/j.euroneuro.2015.03.009","article-title":"Modafinil combined with cognitive training: pharmacological augmentation of cognitive training in schizophrenia","volume":"25","author":"Michalopoulou","year":"2015","journal-title":"Eur Neuropsychopharmacol."},{"key":"2025111023421339600_CIT0076","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1192\/bjp.2023.149","article-title":"Treatment with psychostimulants and atomoxetine in people with psychotic disorders: reassessing the risk of clinical deterioration in a real-world setting","volume":"224","author":"Corbeil","year":"2024","journal-title":"Br J Psychiatry."},{"key":"2025111023421339600_CIT0077","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.schres.2014.01.016","article-title":"d-Cycloserine augmentation of cognitive remediation in schizophrenia","volume":"153","author":"Cain","year":"2014","journal-title":"Schizophr Res."},{"key":"2025111023421339600_CIT0078","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.drugalcdep.2018.07.011","article-title":"Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990-2017: Systematic review and meta-analysis","volume":"191","author":"Hunt","year":"2018","journal-title":"Drug Alcohol Depend."},{"key":"2025111023421339600_CIT0079","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1176\/ajp.95.4.945","article-title":"The results of eighteen months of Benzedrine sulfate therapy in psychiatry","volume":"95","author":"Davidoff","year":"1939","journal-title":"Am J Psychiatry."},{"key":"2025111023421339600_CIT0080","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1001\/archpsyc.1976.01770120029002","article-title":"Hyporesponsivity of chronic schizophrenic patients to dextroamphetamine","volume":"33","author":"Kornetsky","year":"1976","journal-title":"Arch Gen Psychiatry."},{"key":"2025111023421339600_CIT0081","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1176\/ajp.139.8.991","article-title":"d-Amphetamine-induced heterogeneous changes in psychotic behavior in schizophrenia","volume":"139","author":"van Kammen","year":"1982","journal-title":"Am J Psychiatry."},{"key":"2025111023421339600_CIT0082","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.biopsych.2005.09.014","article-title":"Size of treatment effects and their importance to clinical research and practice","volume":"59","author":"Kraemer","year":"2006","journal-title":"Biol Psychiatry."},{"key":"2025111023421339600_CIT0083","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1037\/prj0000244","article-title":"Supplementing intensive targeted computerized cognitive training with social cognitive exercises for people with schizophrenia: An interim report","volume":"40","author":"Fisher","year":"2017","journal-title":"Psychiatr Rehabil J."},{"key":"2025111023421339600_CIT0084","doi-asserted-by":"crossref","first-page":"4751","DOI":"10.1017\/S0033291722001696","article-title":"Aerobic exercise enhances cognitive training effects in first-episode schizophrenia: randomized clinical trial demonstrates cognitive and functional gains","volume":"53","author":"Nuechterlein","year":"2023","journal-title":"Psychol Med."},{"key":"2025111023421339600_CIT0085","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1176\/appi.ajp.2009.09010017","article-title":"The cognitive cost of anticholinergic burden: decreased response to cognitive training in schizophrenia","volume":"166","author":"Vinogradov","year":"2009","journal-title":"Am J Psychiatry."},{"key":"2025111023421339600_CIT0086","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1176\/appi.ajp.2020.20081212","article-title":"Comprehensive characterization of anticholinergic medication burden-associated cognitive impairment in schizophrenia","volume":"178","author":"Joshi","year":"2021","journal-title":"Am J Psychiatry."},{"key":"2025111023421339600_CIT0087","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s40262-013-0038-9","article-title":"Pharmacodynamic, Pharmacokinetic and Pharmacogenetic Aspects of Drugs Used in the Treatment of Alzheimer\u2019s Disease","volume":"52","author":"Noetzli","year":"2013","journal-title":"Clin Pharmacokinet."},{"key":"2025111023421339600_CIT0088","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4088\/JCP.11m07162","article-title":"Minimum clinically important difference in the Positive and Negative Syndrome Scale with data from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE)","volume":"73","author":"Hermes","year":"2012","journal-title":"J Clin Psychiatry."},{"key":"2025111023421339600_CIT0089","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S2215-0366(17)30078-0","article-title":"Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis","volume":"4","author":"Hjorth\u00f8j","year":"2017","journal-title":"Lancet Psychiatry"}],"container-title":["Schizophrenia Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/51\/6\/1529\/62925653\/sbaf015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article-pdf\/51\/6\/1529\/62925653\/sbaf015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T04:42:28Z","timestamp":1762836148000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/schizophreniabulletin\/article\/51\/6\/1529\/8113219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":89,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,4,14]]},"published-print":{"date-parts":[[2025,11,10]]}},"URL":"https:\/\/doi.org\/10.1093\/schbul\/sbaf015","relation":{},"ISSN":["0586-7614","1745-1701"],"issn-type":[{"type":"print","value":"0586-7614"},{"type":"electronic","value":"1745-1701"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,4,14]]}}}